Benjamin G. Cameransi, Jr.;David Anderson;Vincent M. Conklin
发明人:
David Anderson,Benjamin G. Cameransi, Jr.,Vincent M. Conklin
申请号：
US12717588
公开号：
US08110225B2
申请日:
2010.03.04
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
